Business Context and Reporting Period
Company: Viking Therapeutics, Inc. (VKTX)
Filing Type: Form 8-K (Current Report)
Date of Report: February 28, 2024
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Shares Offered: 6,471,000 shares of Common Stock.
- Public Offering Price: $85.00 per share.
- Underwriting Price: $80.305705 per share.
- Over-Allotment Option: Underwriters granted an option to purchase up to 970,650 additional shares within 30 days.
- Gross Proceeds: Approximately $550.0 million (excluding over-allotment).
- Expected Closing Date: On or about March 4, 2024.
Material Changes and Use of Proceeds
This filing represents a significant capital raise event rather than a periodic financial performance report. The Company intends to use the net proceeds for:
- Continued development of programs VK2809, VK2735, and VK0214.
- General research and development.
- Working capital and general corporate purposes.
Guidance, Risks, and Contingencies
- Lock-Up Agreements: Directors and executive officers are restricted from selling securities until May 28, 2024.
- Closing Conditions: The transaction is subject to customary closing conditions; the Company cautioned that the Offering may not close on a timely basis or at all.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the anticipated closing and use of proceeds, which are subject to risks and uncertainties detailed in periodic reports.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting underwriting discounts and expenses.
- Confirm whether the underwriters exercise the over-allotment option for the additional 970,650 shares.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification and termination provisions.
- Monitor subsequent filings for updates on the progress of the VK2809, VK2735, and VK0214 development programs.